The limitations of current cancer nanomedicines include low tumor delivery efficiency, no significant benefit in treatment efficacy, cancer relapse when stopping treatment, and challenges in the manufacturing process; the latter have resulted in shortages and even discontinuation of current liposomal formulations containing chemotherapeutic agents.
Our experienced team is focused on tumor-specific nanoparticle platforms to largely improve delivery efficiency, treatment efficacy and product safety. One novel product is radiotherapeutic nanoparticles containing the beta particle-emitting isotope holmium-166 ( 166Ho) for the treatment of peritoneal metastasis through intraperitoneal (i.p.) administration. The 166Ho nanoparticles are produced by a neutron activation process that minimizes the handling of these highly radioactive nanoparticles. We have demonstrated the predominant accumulation of 166Ho nanoparticles in tumors after i.p. administration to ovarian tumor-bearing mice, resulting in a reduction in tumor burden and prolonged survival. Despite advances in treatment strategies, peritoneal metastasis remains the primary cause of morbidity and mortality in ovarian cancer. With 239,000 women diagnosed worldwide each year, ovarian cancer is the 7th most common cancer in women and has a five-year relative survival rate only 28%. It accounts for more deaths than any other cancer of the female reproductive system. Our immediate goal is to advance the 166Ho product toward clinical trials by demonstrating its safety and efficacy in preclinical animal models.
Primary Indication: Ovarian Peritoneal Metastasis
Intraperitoneal Delivery of 166Ho-nanoparticles
Minimize radiation handling and selective tumor uptake
Manufacture non-radioactive nanoparticles
One step conversion to radioactive nanoparticles by neutron irradiation
Tumor-specific i.p. radiation therapy
Neutron Activation of Holmium Loaded nanoparticles (NPs)
High Tumor Targetability
Prolonged Survival with Low Toxicity
Revolutionary tumor-specific radiation treatment for peritoneal metastasis in late stage ovarian cancers, currently no effective treatment in clinic.
Overcome chemoresistance or other molecular resistance mechanisms. Prolong survival time in various peritoneal metastasis animal models. Tumor specific delivery with reduced toxicity to healthy tissues.
Easy manufacture, limited radiation handling.
No similar products as direct competitors on the market.